According to Zacks, “DSM N V ADR is involved in the Chemicals Industry. Their main focus is on base materials, performance materials, materials processing, base chemicals and fine chemicals and coating resins. They are also involved in the exploration and development of oil and natural gas deposits in the North Sea, as well as the licensing of chemical technology and know-how; in addition the company produces ingredients for bakery products. DSM is a world market leader in a number of products, including caprolactam, melamine and EPDM synthetic rubber. “
Several other research firms have also issued reports on RDSMY. ValuEngine lowered shares of Yext from a strong-buy rating to a buy rating in a report on Friday, May 10th. JPMorgan Chase & Co. lifted their target price on shares of from GBX 2,300 ($30.05) to GBX 2,900 ($37.89) and gave the company a neutral rating in a report on Friday, July 5th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The stock presently has an average rating of Buy and an average price target of $30.00.
RDSMY stock opened at $31.57 on Wednesday. The firm’s 50 day simple moving average is $30.04. Koninklijke DSM has a 52-week low of $19.45 and a 52-week high of $31.75. The stock has a market capitalization of $22.74 billion, a price-to-earnings ratio of 18.25, a price-to-earnings-growth ratio of 2.23 and a beta of 1.41. The company has a quick ratio of 1.68, a current ratio of 2.45 and a debt-to-equity ratio of 0.29.
About Koninklijke DSM
Koninklijke DSM N.V., a science-based company, engages in nutrition, health, and materials businesses in the Netherlands, North America, the United Kingdom, France, Germany, Switzerland, the Asia-Pacific, and internationally.. The company operates through Nutrition, Materials, and Innovation Center segments.
Recommended Story: What is the Dow Jones Industrial Average (DJIA)?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Koninklijke DSM Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Koninklijke DSM and related companies with MarketBeat.com's FREE daily email newsletter.